

EMA/121657/2019

European Medicines Agency decision P/0026/2019

of 22 February 2019

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for avapritinib (EMA-002358-PIP02-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0026/2019

of 22 February 2019

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for avapritinib (EMA-002358-PIP02-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Blueprint Medicines (Netherlands) B.V. on 23 April 2018 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 February 2019, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for avapritinib, film-coated tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for avapritinib, film-coated tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for avapritinib, film-coated tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Blueprint Medicines (Netherlands) B.V., Gustav Mahlerplein 2, 1082 MA – Amsterdam, The Netherlands.

EMA/PDCO/780758/2018
London, 1 February 2019

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002358-PIP02-18

Scope of the application

Active substance(s):

Avapritinib

Condition(s):

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Blueprint Medicines (Netherlands) B.V.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Blueprint Medicines (Netherlands) B.V. submitted for agreement to the European Medicines Agency on 23 April 2018 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 29 May 2018.

Supplementary information was provided by the applicant on 26 October 2018. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- film-coated tablet, age-appropriate oral solid dosage form, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients from 2 to less than 18 years of age with a relapsed/refractory solid tumour harbouring mutations in either KIT or PDGFR-alpha

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age-appropriate formulation
Non-clinical studies	0	Not applicable.

Area	Number of measures	Description
Clinical studies	2	Study 2 Multicentre, open-label, single arm study to evaluate safety, pharmacokinetics (part 1) and anti-tumour activity (part 2) of avapritinib in paediatric patients from 2 to less than 18 years of age with a relapsed/refractory solid tumour harbouring a mutation in KIT or PDGFR-alpha and no available alternative treatment options. (BLU-285-3101) Study 3 Multicentre, open-label, randomized study to evaluate safety, pharmacokinetics and efficacy of avapritinib compared to investigator's choice of therapy in paediatric patients from 2 to less than 18 years of age with a relapsed/refractory solid tumour harbouring a mutation in KIT or PDGFR-alpha selected based on the results of Study 2. (BLU-285-3303)
Extrapolation, modelling and simulation studies	1	Study 4 Modelling and simulation study to evaluate the use and support dosing regimen of avapritinib in children and adolescents from 2 to less than 18 years of age with a relapsed/refractory solid tumour harbouring a mutation in KIT or PDGFR-alpha. (AVA-PIP-M&S-1)
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes